Merck-Moderna melanoma vaccine combo shows phase 3 win for delaying recurrence
TL;DR Summary
Merck and Moderna reported positive phase 3 results for a personalized mRNA cancer vaccine used with Keytruda in melanoma patients who had surgery, significantly extending disease-free survival and reducing the risk of distant metastasis versus Keytruda alone; safety was comparable to vaccines, and the teams will pursue regulatory submissions while continuing to assess overall survival.
- Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% cnbc.com
- Moderna shares surge as melanoma vaccine with Merck succeeds in large trial CNN
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT
- Moderna’s stock doubles on promising cancer-vaccine results marketwatch.com
- Cancer treatment could face landmark moment with promising vaccine The Washington Post
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
3 min
vs 4 min read
Condensed
93%
754 → 55 words
Want the full story? Read the original article
Read on cnbc.com